These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 22289817)
1. [Mix-up of Fc receptors in the response to monoclonal antibodies]. Teillaud JL Med Sci (Paris); 2012 Jan; 28(1):11-3. PubMed ID: 22289817 [No Abstract] [Full Text] [Related]
2. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400 [TBL] [Abstract][Full Text] [Related]
3. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
16. In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapy. Banz A; Cremel M; Rembert A; Godfrin Y Vaccine; 2010 Apr; 28(17):2965-72. PubMed ID: 20188177 [TBL] [Abstract][Full Text] [Related]
17. The use of agonistic anti-CD40 therapy in treatments for cancer. Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570 [TBL] [Abstract][Full Text] [Related]
18. Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma. Nisticò P; Mortarini R; De Monte LB; Mazzocchi A; Mariani M; Malavasi F; Parmiani G; Natali PG; Anichini A J Clin Invest; 1992 Sep; 90(3):1093-9. PubMed ID: 1387883 [TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245 [TBL] [Abstract][Full Text] [Related]
20. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]